Cargando…
Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466854/ https://www.ncbi.nlm.nih.gov/pubmed/34576930 http://dx.doi.org/10.3390/molecules26185460 |
_version_ | 1784573246540087296 |
---|---|
author | Velic, Denis Demeyer, Alexandre Peterlini, Thibaut Benhelli-Mokrani, Houda Mathé-Allainmat, Monique Masson, Jean-Yves Fleury, Fabrice |
author_facet | Velic, Denis Demeyer, Alexandre Peterlini, Thibaut Benhelli-Mokrani, Houda Mathé-Allainmat, Monique Masson, Jean-Yves Fleury, Fabrice |
author_sort | Velic, Denis |
collection | PubMed |
description | RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated resistance has justified the development of targeted inhibitors. One of the first molecules described to inhibit RAD51 was the 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid (DIDS) molecule. This small molecule is effective in inhibiting different functions of RAD51, however its mode of action and the chemical functions involved in this inhibition have not been identified. In this work, we used several commercial molecules derived from DIDS to characterize the structural determinants involved in modulating the activity of RAD51. By combining biochemical and biophysical approaches, we have shown that DIDS and two analogs were able to inhibit the binding of RAD51 to ssDNA and prevent the formation of D-loop by RAD51. Both isothiocyanate substituents of DIDS appear to be essential in the inhibition of RAD51. These results open the way to the synthesis of new molecules derived from DIDS that should be greater modulators of RAD51 and more efficient for HR inhibition. |
format | Online Article Text |
id | pubmed-8466854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84668542021-09-27 Molecular Determinant of DIDS Analogs Targeting RAD51 Activity Velic, Denis Demeyer, Alexandre Peterlini, Thibaut Benhelli-Mokrani, Houda Mathé-Allainmat, Monique Masson, Jean-Yves Fleury, Fabrice Molecules Article RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated resistance has justified the development of targeted inhibitors. One of the first molecules described to inhibit RAD51 was the 4,4′-diisothiocyanato-stilbene-2,2′-disulfonic acid (DIDS) molecule. This small molecule is effective in inhibiting different functions of RAD51, however its mode of action and the chemical functions involved in this inhibition have not been identified. In this work, we used several commercial molecules derived from DIDS to characterize the structural determinants involved in modulating the activity of RAD51. By combining biochemical and biophysical approaches, we have shown that DIDS and two analogs were able to inhibit the binding of RAD51 to ssDNA and prevent the formation of D-loop by RAD51. Both isothiocyanate substituents of DIDS appear to be essential in the inhibition of RAD51. These results open the way to the synthesis of new molecules derived from DIDS that should be greater modulators of RAD51 and more efficient for HR inhibition. MDPI 2021-09-08 /pmc/articles/PMC8466854/ /pubmed/34576930 http://dx.doi.org/10.3390/molecules26185460 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Velic, Denis Demeyer, Alexandre Peterlini, Thibaut Benhelli-Mokrani, Houda Mathé-Allainmat, Monique Masson, Jean-Yves Fleury, Fabrice Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title | Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title_full | Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title_fullStr | Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title_full_unstemmed | Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title_short | Molecular Determinant of DIDS Analogs Targeting RAD51 Activity |
title_sort | molecular determinant of dids analogs targeting rad51 activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466854/ https://www.ncbi.nlm.nih.gov/pubmed/34576930 http://dx.doi.org/10.3390/molecules26185460 |
work_keys_str_mv | AT velicdenis moleculardeterminantofdidsanalogstargetingrad51activity AT demeyeralexandre moleculardeterminantofdidsanalogstargetingrad51activity AT peterlinithibaut moleculardeterminantofdidsanalogstargetingrad51activity AT benhellimokranihouda moleculardeterminantofdidsanalogstargetingrad51activity AT matheallainmatmonique moleculardeterminantofdidsanalogstargetingrad51activity AT massonjeanyves moleculardeterminantofdidsanalogstargetingrad51activity AT fleuryfabrice moleculardeterminantofdidsanalogstargetingrad51activity |